Dr. Arun Singh on an Early-Stage Trial of Immunotherapy for Advanced Sarcomas
Arun Singh, MD, assistant professor, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), discusses a phase Ib/II trial of immunotherapy for patients with advanced sarcoma.
Arun Singh, MD, assistant professor, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), discusses a phase Ib/II trial of immunotherapy for patients with advanced sarcoma.
This trial examined adoptive cellular therapy with autologous lymphocytes genetically modified to express an NY-ESO-1-specific T-cell receptor and dendritic cell vaccination with or without ipilimumab (Yervoy). Patients who had failed standard therapies were evaluated.
In this trial, seven patients were evaluated and two responded. Of those responders, one had 50-60 metastases in their lungs and most shrunk or were completely eliminated. The other patient experienced a complete response that has lasted 15 months.
Because ipilimumab has been added and nivolumab (Opdivo) will be added, Singh says, researchers want to determine which patients will respond best while experiencing minimal side effects.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
